COYA 303 / Coya Therap - LARVOL DELTA

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results (Businesswire) - "Q2 2025: Submission of additional nonclinical data to support the start of the COYA-302 Phase 2 trial in patients with ALS; Upon IND acceptance and first patient dosing of COYA-302 in ALS, eligible to receive milestone payments of $8.4 million from strategic partner, Dr. Reddy’s Laboratories (DRL); Q2 2025: Publication of COYA-303 combination mechanistic data; Q2 2025: Publication of data documenting role of inflammation in Parkinson’s Disease; Q2 2025: ALS Biomarker data. Publication of longitudinal data on Neurofilament Light Chain (NfL) and oxidative stress markers in patients with ALS."

Biomarker • Clinical data • IND • Preclinical • Amyotrophic Lateral Sclerosis • Immunology • Inflammation

Coya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimer’s Disease Using GLP-1 Agonists and Combinations (Businesswire) - "Coya Therapeutics, Inc...announces that Chief Executive Officer Arun Swaminathan, Ph.D. and Dr. Stanley H. Appel, Professor of Neurology, Houston Methodist Hospital will participate in a BTIG hosted KOL webcast 'Is Alzheimer’s next for GLP-1s and Combos?' on February 27, 2025 to discuss the potential treatment of Alzheimer’s disease using GLP-1 agonists and combination therapy...Coya recently announced the expansion of its investigational pipeline and advancement of COYA 303 for the treatment of inflammatory diseases."

Clinical data • Alzheimer's Disease • Inflammation

Coya Therapeutics Announces Pipeline Expansion - COYA 303: COYA 301 in Combination with GLP-1 Receptor Agonist for the Treatment of Inflammatory Diseases (Businesswire) - "Coya Therapeutics...announces the expansion of its investigational pipeline and advancement of COYA 303 for the treatment of inflammatory diseases. Sustained inflammatory responses driven by dysfunctional immune regulation is a hallmark of serious autoimmune and neurodegenerative diseases...In a preclinical study, COYA 303 exhibited a dual immunomodulatory mechanism of action resulting in an additive/synergistic anti-inflammatory effect, which the Company believes was due to increased Treg function and suppressed pro-inflammatory myeloid cells and responder T cells. Coya intends to publish the results of this study in a peer-reviewed publication in the first half of 2025 and has filed several patent applications to protect the compound....Following the positive results of this study, Coya intends to continue ongoing strategic discussions to advance COYA 303 through IND-enabling studies and into the clinic."

Pipeline update • Preclinical • CNS Disorders • Immunology • Inflammation